Investor Relations

Rigel's Mission

Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer.

Latest News

Rigel Highlights Initial Data from Ongoing Phase 1b Study Evaluating R289 in LR-MDS at the 66th ASH Annual Meeting and Exposition

View Press Release View All

Rigel Announces R289 Granted Fast Track Designation by the FDA for Lower-Risk MDS

Rigel to Present at the Jefferies London Healthcare Conference

Rigel Reports Third Quarter 2024 Financial Results and Provides Business Update

Recent Event

66th American Society of Hematology Annual Meeting and Exposition

View All

Latest Financial Results

Q3 2024

Quarter Ended Sep 30, 2024
Earnings Release
PDF HTML
Audio
Earnings Webcast
Earnings Presentation
PDF
10-Q Filing
PDF HTML
XBRL
ZIP XLS HTML

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2023

Report Links

mail icon

Sign Up For Email Alerts

Receive updates straight into your inbox

Sign up today

Investor Contact Information

Company

Rigel Pharmaceuticals, Inc.
611 Gateway Blvd
Suite 900
South San Francisco, CA 94080

Investor Relations

Rigel Pharmaceuticals, Inc.
ir@rigel.com

Transfer Agent

EQ Shareowner Services
T: 800-401-1957